title: Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
creator: Wang, Shuzhen
creator: Zhang, Xin
creator: Han, Tao
creator: Xie, Wen
creator: Li, Yonggang
creator: Ma, Hong
creator: Liebe, Roman
creator: Weng, Honglei
creator: Ding, Hui-Guo
subject: 610
subject: 610 Medical sciences Medicine
description: Background: Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-month survival of decompensated cirrhotic patients with and without hyponatremia.       Methods: Two hundred forty-nine decompensated cirrhotic patients with or without hyponatremia were enrolled in a multicenter cohort study. Patients were divided into two groups according to receiving either tolvaptan or placebo treatment for 7-day. Subsequently, the patients were followed up for 6 months.       Results: Two hundred thirty patients, including 98 with hyponatremia (tolvaptan vs. placebo: 69 vs. 29) finished the study. Tolvaptan did not alter serum sodium levels and survival outcome of decompensated cirrhotic patients without hyponatremia. However, tolvaptan treatment remarkably improved serum sodium levels and six-month survival in patients with hyponatremia. Following tolvaptan treatment, serum sodium levels were restored to normal in 63.8% of patients, whereas in patients receiving placebo, only 36.2% showed the same effect (P < 0.05). Compared to a six-month survival rate of 68.97% in patients receiving placebo, the survival rate in tolvapatan-treated patients was 89.94% (P < 0.05). Furthermore, six-month survival rate in the tolvaptan-treated hyponatremia patients with resolved serum sodium was 81.32%, whereas the survival in those with unresolved serum sodium was only 24% (P < 0.05).    Conclusions: Tolvaptan improves short term survival in most decompensated cirrhotic hyponatremia patients with resolved serum sodium.    Trials registration: Clinical trial one: ClinicalTrials.gov ID: NCT00664014  , Registered on April 14, 2008. Clinical trial two: ClinicalTrials.gov ID: NCT01349335  , Registered on March 5, 2010. Clinical trial three: ClinicalTrials.gov ID: NCT01349348  , Registered on May 4, 2011.
publisher: BioMed Central
date: 2018
type: Article
type: info:eu-repo/semantics/article
type: NonPeerReviewed
format: application/pdf
identifier: https://archiv.ub.uni-heidelberg.de/volltextserverhttps://archiv.ub.uni-heidelberg.de/volltextserver/25459/1/12876_2018_Article_857.pdf
identifier: DOI:
identifier: urn:nbn:de:bsz:16-heidok-254597
identifier:   Wang, Shuzhen ; Zhang, Xin ; Han, Tao ; Xie, Wen ; Li, Yonggang ; Ma, Hong ; Liebe, Roman ; Weng, Honglei ; Ding, Hui-Guo  (2018) Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.  BMC Gastroenterology, 18 (137).  pp. 1-8.  ISSN 1471-230X     
relation: https://archiv.ub.uni-heidelberg.de/volltextserver/25459/
rights: info:eu-repo/semantics/openAccess
rights: Please see front page of the work (Sorry, Dublin Core plugin does not recognise license id)
language: eng